Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

6/24/2022
BreakingChinaPharmaRegulationRetina
EyePoint and OcuMension Announce Yutiq’s Approval for Uveitis in China
EyePoint and OcuMension Announce Yutiq’s Approval for Uveitis in China

EyePoint Pharmaceuticals and OcuMension Therapeutics announced June 21 that China regulators had approved Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg for the treatment of chronic no...

6/24/2022
BreakingDealsRetina
Apellis Plans IND with Partner Affilogic for C3 Inhibitor in Wet AMD and GA
Apellis Plans IND with Partner Affilogic for C3 Inhibitor in Wet AMD and GA

Apellis Pharmaceuticals announced June 22 that it and partner Affilogic, of France, plan to submit an investigational new drug (IND) application to the US FDA within the next 12 months for APL-2006...

6/24/2022
BreakingPharmaRegulation
Medicare Could Have Saved $3.6B Paying Same Drug Prices as Those at Mark Cuban Pharmacy
Medicare Could Have Saved $3.6B Paying Same Drug Prices as Those at Mark Cuban Pharmacy

Medicare could have saved $3.6 billion in 2020 by purchasing generic drugs at the prices offered by Cost Plus Drug Company, the online pharmacy of Mark Cuban, according to research published June 2...

6/24/2022
BreakingRetinaStudy
Researchers Revive Photoreceptors in Organ Donor Eyes
Researchers Revive Photoreceptors in Organ Donor Eyes

Researchers at the University of Utah John A. Moran Eye Center have revived photoreceptors in organ donor eyes and restored communication between them, according to research published in May in the...

6/24/2022
BreakingRetinaStudy
Researchers Create ‘Self-Plugging’ Microneedle for IVT Drug Delivery
Researchers Create ‘Self-Plugging’ Microneedle for IVT Drug Delivery

Researchers say they’ve developed a “self-plugging” microneedle to deliver drugs to the eye that will reduce some of the risks of intravitreal injection with hypodermic needles, according to work p...

6/24/2022
BreakingClinical TrialDry EyeRegulation
Aldeyra Announces Positive Phase III Results for Reproxalap in Dry Eye
Aldeyra Announces Positive Phase III Results for Reproxalap in Dry Eye

Aldeyra Therapeutics, of Lexington, Massachusetts, reported June 8 that its Phase III TRANQUILITY-2 trial for dry eye candidate reproxalap met its primary endpoints. Reproxalap was statistically su...

6/24/2022
BreakingIndustryRetina
Foundation Fight Blindness Names Jason Menzo as CEO, Russell Kelley as Head of RD Fund
Foundation Fight Blindness Names Jason Menzo as CEO, Russell Kelley as Head of RD Fund

The Foundation Fighting Blindness reported June 21 that it had promoted Jason Menzo to chief executive officer (CEO) and Russell Kelley, PhD, MBA, to managing director of the Retinal Degeneration F...

6/24/2022
BreakingGene TherapyIndustry
Opus Genetics Appoints Ben Yerxa, PhD, as Permanent CEO
Opus Genetics Appoints Ben Yerxa, PhD, as Permanent CEO

Opus Genetics announced June 21 thatBen Yerxa, PhD, would become permanent chief executive officer after serving as acting CEO. Yerxa will leave his other positions as CEO of Foundation Fighting Bl...

6/21/2022
EarningsNewsletterRevenue
Ophthalmic Company Revenue Increases 8.2 Percent in First Quarter of 2022
Ophthalmic Company Revenue Increases 8.2 Percent in First Quarter of 2022

Ophthalmic manufacturer revenue in Q1-2022 totaled $10.9 billion. Three public companies reported record-high earnings in Q1-2022 compared with the past three years. Revenue increased 8.2 percent o...

6/21/2022
CataractGlaucomaNewsletterRefractiveRetina
Surgeons Report 16.9 Percent Increase in Q1-2022 Ophthalmic Procedure Volume
Surgeons Report 16.9 Percent Increase in Q1-2022 Ophthalmic Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 16.9 percent in Q1-2022 compared with the same quarter in 2021, according to Market Scope’s latest surveys. Year-over-year performa...

6/21/2022
BiologicsNewsletterRetina
Outlook, Xbrane Retool Submissions for Retinal Biosimilars, While Byooviz Readies for Launch in the US
Outlook, Xbrane Retool Submissions for Retinal Biosimilars, While Byooviz Readies for Launch in the US

Two biosimilars have hit a snag on the path to approval for the US retinal treatment market, while two others are advancing toward commercialization. Outlook Therapeutics reported May 31 that it ha...

6/21/2022
AtlasNewsletterRefractive
Metro Demographics Drive LVC Surgery Rates and Potential Refractive Patient Pool in the US
Metro Demographics Drive LVC Surgery Rates and Potential Refractive Patient Pool in the US

Numerous factors are influencing LVC procedure volumes and conversion rates in the United States, including the growing wealth and size of the millennial and Generation Z populations and increasing...

Past News Stories

6/21/2022
AcquisitionsCornealNewsletter
Corza Medical Acquires Barron Precision Instruments in Second Add-On Purchase
Corza Medical Acquires Barron Precision Instruments in Second Add-On Purchase

Private equity firm GTCR announced June 8 that Corza Medical, one of its portfolio companies, had acquired Barron Precision Instruments. Terms of the deal were not disclosed. Barron, founded in 194...

6/21/2022
AcquisitionsInstrumentsNewsletter
Rayner Buys Stake in Belgium Manufacturer of Recyclable Ophthalmic Surgical Instruments
Rayner Buys Stake in Belgium Manufacturer of Recyclable Ophthalmic Surgical Instruments

UK-based Rayner announced June 8 that it had acquired a stake in Hasa Optix, a Belgium-based manufacturer of recyclable single-use ophthalmic surgical instruments and instrument sets. Hasa Optix, f...

6/21/2022
NewsletterPharmaRegulation
Bausch + Lomb’s Lumify Expands to Canada; Redness Relief Drops Had 2021 Sales of $108M
Bausch + Lomb’s Lumify Expands to Canada; Redness Relief Drops Had 2021 Sales of $108M

Bausch + Lomb announced May 24 that its Lumify eye drops had gained Health Canada approval to relieve redness in adult patients due to minor eye irritations. Lumify, a formulation of low-dose brimo...

6/21/2022
CataractNewsletterRegulation
LENSAR Gains FDA Clearance of Femtosecond Technology in ALLY Femto-Phaco Platform
LENSAR Gains FDA Clearance of Femtosecond Technology in ALLY Femto-Phaco Platform

LENSAR announced June 13 that it had received US FDA clearance for the femtosecond technology in its ALLY Adaptive Cataract Treatment System, a femto-phaco platform designed to allow surgeons to pe...

6/21/2022
NewsletterScope of Practice
Colorado Expands Scope of Practice for ODs to Include Laser Procedures, Cross-linking
Colorado Expands Scope of Practice for ODs to Include Laser Procedures, Cross-linking

The American Optometric Association reported June 8 that Colorado had expanded the scope of practice for optometrists to include laser procedures and corneal cross-linking. Colorado Gov. Jared Poli...

6/21/2022
NewsletterRefractiveRegulationRetina
Select US FDA Approvals and Clearances in May 2022
Select US FDA Approvals and Clearances in May 2022

The US FDA granted three clearances through the ophthalmic device division using the 510(k) pathway in May 2022, according to the agency’s database. Two were notable. Vista Ophthalmics gained clear...

6/21/2022
DiagnosticNewsletterRetina
MacuLogix Faces Insurmountable Debt, Moves to Wind Down Operations
MacuLogix Faces Insurmountable Debt, Moves to Wind Down Operations

MacuLogix Inc., maker of the AdaptDx dark adaptation screener for age-related macular degeneration (AMD), cannot pay $23 million it owes to creditors and has filed to wind down the business, accord...

6/21/2022
Clinical TrialGene TherapyNewsletter
Gene Therapy Candidate for LHON Fails to Show Efficacy in Early Trial; Researchers Drop Program
Gene Therapy Candidate for LHON Fails to Show Efficacy in Early Trial; Researchers Drop Program

Researchers at the Bascom Palmer Eye Institute reported June 1 that a 28-patient Phase I clinical trial of a gene therapy candidate for Leber hereditary optic neuropathy (LHON) failed to improve or...

6/21/2022
CataractNewsletterPharma
Oxysterol Drug Compound Shows Promise as Cataract Treatment
Oxysterol Drug Compound Shows Promise as Cataract Treatment

Researchers have successfully tested a cataract treatment candidate using an oxysterol compound, VP1-001. The international team, led by scientists at UK-based Anglia Ruskin University, reported Ma...

6/21/2022
DiagnosticNewsletterRetina
Study of Orbis AI Screenings in Rwanda Shows Immediate Feedback Improves Diabetic Eye Care
Study of Orbis AI Screenings in Rwanda Shows Immediate Feedback Improves Diabetic Eye Care

Orbis International reported June 6 that new research demonstrated that diabetic retinopathy (DR) screenings supported by artificial intelligence (AI) enhanced patients’ speed and uptake of referra...

6/21/2022
NewsletterRegulationRetina
US FDA Expands Labeling for Novartis’ Beovu to Include DME Indication
US FDA Expands Labeling for Novartis’ Beovu to Include DME Indication

Swiss drugmaker Novartis announced June 1 that the US FDA had approved Beovu (brolucizu-mab-dbll) 6 mg to treat diabetic macular edema (DME). Beovu is approved to treat wet age-related macular dege...

6/21/2022
ChinaNewsletterRetina
Chugai Launches Vabysmo in Japan for Treating Wet AMD and DME
Chugai Launches Vabysmo  in Japan for Treating Wet AMD and DME

Tokyo-based Chugai Pharmaceutical Co. reported May 25 that it had launched Vabysmo (faricimab) in Japan for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (D...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more